Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Analysis: Pandemic fatigue makes the case for boosters a harder sell

Stock MarketsJan 10, 2022 08:46AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: A nurse prepares a fourth dose of coronavirus disease (COVID-19) vaccine as part of a trial in Israel, at Sheba Medical Center in Ramat Gan, Israel December 27, 2021. REUTERS/Ronen Zvulun

By Julie Steenhuysen and Maayan Lubell

CHICAGO (Reuters) - Some nations are already looking to a fourth vaccine dose to help contend with a huge Omicron-driven spike in COVID-19 cases, but early signs suggest repeat vaccination may be a hard sell as beleaguered populations enter their third pandemic year.

Uptake of the first round of boosters in recent months - a third shot for most - has lagged initial vaccinations.

Disease experts say that rapidly shifting public health messaging in the face of a quickly-mutating virus has bred confusion and mistrust over the benefit of boosters.

The Omicron variant of the coronavirus has more than 30 mutations on the spike protein - the target of most current COVID-19 vaccines. These changes have increased Omicron's transmissibility, and allowed the virus to evade protection from symptomatic disease induced by vaccines and prior infection. Yet vaccines remain the critical tool in preventing severe disease and death, experts say.

Lab studies suggest that a third shot of vaccines from Pfizer (NYSE:PFE) Inc/BioNTech SE or Moderna (NASDAQ:MRNA) Inc, already offered as a booster in many countries, can restore much of that lost protection.

But UK government data released in December found that increased antibody protection against Omicron from the booster wanes after 10 weeks, raising questions about whether additional shots would be needed in short order.

Based on its lab studies, Pfizer chief scientist Mikael Dolsten told CBS News in early December that it is "very likely" a fourth dose of the vaccine would be needed within months if Omicron persists as the dominant version of coronavirus. Israel is already administering a fourth dose of the Pfizer/BioNTech shot to people over the age of 60, immunocompromised patients and healthcare workers to protect them against an Omicron surge.

Government officials there have cited early evidence that the extra shot was safe and provoked a five-fold boost in antibodies that can protect against infection and severe disease.

In the United States, White House medical adviser Dr. Anthony Fauci in late December said it was "conceivable" that an additional booster would be needed, but that the decision on further doses will be based on not yet available information on the durability of existing booster shots.

Immunocompromised individuals in the United States are offered three doses of vaccine as part of their initial series of shots, and a single booster shot six months later. Health officials in the Netherlands, UK and Germany have also floated the notion of the need for additional booster shots, while French officials have said they will not make a decision until mid-February or March, when more data are available. DO I NEED THIS? Yasmin Maor, a member of the Israeli advisory panel that recommended a fourth round of shots for those most at risk from COVID, told a news conference last month that people may need to be prepared to receive multiple shots a year to address a pandemic of this magnitude.

For the wider public, that message may not be welcome, even among those willing to be vaccinated in the first round of inoculations. Recent health data shows that 9% of the Israeli population has "invalid" vaccine status, meaning they took their second shot but not a booster.

In Russia, data are sparse, but at the last update on Dec. 12, Russian health minister Mikhail Murashko said 10 million people were boosted, compared with 73 million Russians - or about half the population - who received an initial round of shots.

In the United States, 62% of the population, or 207 million people, were considered fully vaccinated, as of Jan. 7. A little more than a third of that number - 73 million - has received a booster dose. Some experts have suggested a booster should be included in a new definition of fully vaccinated.

Dr. Angela Rasmussen, a virologist at the University of Saskatchewan in Canada, said in the United States boosters were portrayed as the way the country exits the pandemic. But Omicron's ability to infect many people who have received a booster dose - albeit typically with milder illness - has changed that narrative.

"There's tons and tons and tons of anecdotal stories out there about boosted people getting Omicron, and I think a lot of people are saying, "What's the rush? Why do I even need to do this?," Rasmussen said.

The reason, she said, is because although they may not prevent all infections, booster shots will keep people from winding up in an intensive care unit. Part of the frustration stems from the nature of the ever-mutating virus itself, which has forced frequent policy updates on everything from mask-wearing to quarantine requirements that have left people confused and distrustful.

Said Jason Gallagher, an infectious disease expert at Temple University's School of Pharmacy: "People are looking for a degree of certainty that can't exist in a situation that's constantly changing."

Analysis: Pandemic fatigue makes the case for boosters a harder sell
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (3)
Roop Misir
Roop Misir Jan 10, 2022 9:23AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Disease experts say that rapidly shifting public health messaging in the face of a quickly-mutating virus has bred confusion and mistrust over the benefit of boosters. Can analgesics and cold medicines be as effective as booster jabs?
Jeremy Johnson
Jeremy Johnson Jan 10, 2022 9:04AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
It's also called "buyer's remorse"
Corey DeLaplain
SniperSam Jan 10, 2022 6:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Notice how this article doesn't once mention how much weaker the Omnicron variant is, to the point of a common cold to mild flu!
Al Ose
Al Ose Jan 10, 2022 6:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
If you are boosted. I know 2 invacced who were laid out for a week. Epic night sweats
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email